Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

Anna S Linehan,1 Orla M Fitzpatrick,1 Patrick G Morris1,2 1Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; 2Department of Medical Oncology, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence: Patrick G MorrisBeaumont Hospital, Dublin, 9, IrelandTel +353...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Linehan AS, Fitzpatrick OM, Morris PG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	antibody-drug conjugate ds8201 her2 trastuzumab deruxtecan trastuzumab emtansine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/5755840965e249f389c2e1f705773c31
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5755840965e249f389c2e1f705773c31
record_format	dspace
spelling	oai:doaj.org-article:5755840965e249f389c2e1f705773c312021-12-02T11:03:10ZProfile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review1179-1314https://doaj.org/article/5755840965e249f389c2e1f705773c312021-02-01T00:00:00Zhttps://www.dovepress.com/profile-of-trastuzumab-deruxtecan-in-the-management-of-patients-with-h-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Anna S Linehan,1 Orla M Fitzpatrick,1 Patrick G Morris1,2 1Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; 2Department of Medical Oncology, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence: Patrick G MorrisBeaumont Hospital, Dublin, 9, IrelandTel +353 1 8092010Email patrickmorris@beaumont.ieAbstract: Trastuzumab deruxtecan is a novel antibody–drug conjugate for the treatment of advanced solid tumors, including breast cancer, which overexpress or have amplification of the human epidermal growth factor receptor 2 (HER2). The novel structure of this exciting new agent means that it can deliver a highly potent cytotoxic agent to HER2-expressing tissues resulting in selective killing of cancer cells. In phase I and II trials, trastuzumab deruxtecan has shown impressive response rates in heavily pretreated populations, including patients who had received prior treatment with trastuzumab emtansine, another highly active antibody–drug conjugate. The most common side effects are gastrointestinal and hematological. Importantly, a high rate of interstitial lung disease was seen in early trials, but this appears manageable in most patients with corticosteroids. In light of its efficacy, this promising new drug may change the treatment paradigm of HER2-positive breast cancer.Keywords: antibody-drug conjugate, DS8201, HER2, trastuzumab deruxtecan, trastuzumab emtansineLinehan ASFitzpatrick OMMorris PGDove Medical Pressarticleantibody-drug conjugateds8201her2trastuzumab deruxtecantrastuzumab emtansineNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 13, Pp 151-159 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antibody-drug conjugate ds8201 her2 trastuzumab deruxtecan trastuzumab emtansine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	antibody-drug conjugate ds8201 her2 trastuzumab deruxtecan trastuzumab emtansine Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Linehan AS Fitzpatrick OM Morris PG Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
description	Anna S Linehan,1 Orla M Fitzpatrick,1 Patrick G Morris1,2 1Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; 2Department of Medical Oncology, Royal College of Surgeons in Ireland, Dublin, IrelandCorrespondence: Patrick G MorrisBeaumont Hospital, Dublin, 9, IrelandTel +353 1 8092010Email patrickmorris@beaumont.ieAbstract: Trastuzumab deruxtecan is a novel antibody–drug conjugate for the treatment of advanced solid tumors, including breast cancer, which overexpress or have amplification of the human epidermal growth factor receptor 2 (HER2). The novel structure of this exciting new agent means that it can deliver a highly potent cytotoxic agent to HER2-expressing tissues resulting in selective killing of cancer cells. In phase I and II trials, trastuzumab deruxtecan has shown impressive response rates in heavily pretreated populations, including patients who had received prior treatment with trastuzumab emtansine, another highly active antibody–drug conjugate. The most common side effects are gastrointestinal and hematological. Importantly, a high rate of interstitial lung disease was seen in early trials, but this appears manageable in most patients with corticosteroids. In light of its efficacy, this promising new drug may change the treatment paradigm of HER2-positive breast cancer.Keywords: antibody-drug conjugate, DS8201, HER2, trastuzumab deruxtecan, trastuzumab emtansine
format	article
author	Linehan AS Fitzpatrick OM Morris PG
author_facet	Linehan AS Fitzpatrick OM Morris PG
author_sort	Linehan AS
title	Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
title_short	Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
title_full	Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
title_fullStr	Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
title_full_unstemmed	Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
title_sort	profile of trastuzumab deruxtecan in the management of patients with her2-positive unresectable or metastatic breast cancer: an evidence-based review
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/5755840965e249f389c2e1f705773c31
work_keys_str_mv	AT linehanas profileoftrastuzumabderuxtecaninthemanagementofpatientswithher2positiveunresectableormetastaticbreastcanceranevidencebasedreview AT fitzpatrickom profileoftrastuzumabderuxtecaninthemanagementofpatientswithher2positiveunresectableormetastaticbreastcanceranevidencebasedreview AT morrispg profileoftrastuzumabderuxtecaninthemanagementofpatientswithher2positiveunresectableormetastaticbreastcanceranevidencebasedreview
_version_	1718396288510197760

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review

Ejemplares similares